978P Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)

Claudia Angela Maria Fulgenzi; Yi‐Hsiang Huang; Anwaar Saeed; Lorenza Rimassa; Martin Schoenlein; Fabio Piscaglia; Ahmed O. Kaseb; Arndt Vogel; Dominik Bettinger; Marianna Silletta; Masatoshi Kudo; Caterina Vivaldi; Bernhard Scheiner; Susanna V. Ulahannan; Peter R. Galle; Wei‐Fan Hsu; Alessandro Parisi; Hong Jae Chon; David J. Pinato; Celina Ang

doi:10.1016/j.annonc.2023.09.2123

Related publications

Article2024

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab

Meng Wu, Claudia A M Fulgenzi, Alessio Cortellini, Ciro Celsa, Giulia Francesca Manfredi, Bernardo Stefanini, Linda Y. Wu, Yi‐Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia I. Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna V. Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei‐Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

Article2025

Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama,

Article2024

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Federico Rossari, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone,

Article2023

165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

Elisabeth Amadeo, M. Persano, Toshifumi Tada, Goki Suda, S. Shimose, Masatoshi Kudo, Changhoon Yoo, Federico Rossari, Francesco Vitiello, A. Casadei Gardini, M. Rimini

Article2020

Outcomes of patients (pts) with advanced gastro-intestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib (IM) as first-line treatment.

Alice Boilève, Armelle Dufresne, Ali N. Chamseddine, Sarah Dumont, M. Brahmi, Julien Adam, Etienne Rouleau, Marie Karanian, Véronique Haddad, Matthieu Faron, Charles Honoré, Pierre Méeus, Axel Le Cesne, Jean Yves Blay, Olivier Mir